Acute Kidney Injury Treatment Approach

Initial Management

• The American College of Cardiology recommends reviewing all medications and withdrawing diuretics, nephrotoxic drugs, vasodilators, and NSAIDs in patients with AKI 2
• The American Journal of Kidney Diseases suggests performing plasma volume expansion in patients with clinically suspected hypovolemia using crystalloids as first-line fluid therapy 3
• For patients with cirrhosis and ascites with AKI, the Gut journal recommends administering intravenous albumin at 1 g/kg bodyweight for two consecutive days 2, 1
• The Praxis Medical Insights guideline recommends targeting mean arterial pressure of at least 65 mmHg to ensure adequate renal perfusion in prerenal AKI 1

Management Based on AKI Stage

• The Gut journal suggests close monitoring of renal function and urine output in Stage 1 AKI 2
• The Praxis Medical Insights guideline recommends considering vasopressor therapy if fluid resuscitation fails to restore adequate blood pressure in Stage 2-3 AKI 1
• For hepatorenal syndrome AKI (HRS-AKI), the Praxis Medical Insights guideline suggests administering vasoactive agents (terlipressin, norepinephrine, or midodrine plus octreotide) along with albumin 1

Fluid Management

• The American Journal of Kidney Diseases recommends using isotonic crystalloids rather than colloids as initial management for volume expansion 3
• The American Journal of Kidney Diseases suggests avoiding hydroxyethyl starches due to increased risk of AKI 3
• The Praxis Medical Insights guideline recommends monitoring for fluid overload using urine output, vital signs, and when indicated, echocardiography 1

Medication Management

• The Praxis Medical Insights guideline states that diuretics should not be used to prevent or treat AKI except for managing volume overload 4
• The Praxis Medical Insights guideline warns against the "triple whammy" combination of NSAIDs, diuretics, and ACE inhibitors/ARBs, which significantly increases AKI risk 1
• The Praxis Medical Insights guideline notes that each additional nephrotoxin increases the odds of developing AKI by 53% 1, 4

Renal Replacement Therapy (RRT) Indications

• The Praxis Medical Insights guideline recommends individualizing the timing of RRT based on the patient's overall clinical condition 1

Monitoring and Follow-up

• The Nature Reviews Nephrology journal recommends reassessing the etiology and considering nephrology consultation for patients with persistent AKI (>48 hours) 5
• The Praxis Medical Insights guideline suggests monitoring electrolytes every 12-24 hours during acute management 4
• The Nature Reviews Nephrology journal notes that timed urine creatinine clearance is currently the best available estimate of kidney function for patients with persistent AKI in the steady state 5
• The Nature Reviews Nephrology journal warns that eGFR equations (MDRD, CKD-EPI) are not accurate for assessment of renal function in persistent AKI 5

Prevention of AKI Progression

• The Praxis Medical Insights guideline recommends continuing nephrotoxin avoidance during the recovery phase to prevent re-injury 1
• The American Journal of Kidney Diseases suggests considering clinical follow-up after AKI, particularly for patients with severe AKI (requiring temporary RRT) or persisting renal dysfunction at hospital discharge 3

Common Pitfalls to Avoid

• The Praxis Medical Insights guideline warns against using furosemide in hemodynamically unstable patients with AKI, as it can precipitate volume depletion and further renal hypoperfusion 4
• The Nature Reviews Nephrology journal advises against using eGFR equations designed for CKD to assess renal function in AKI 5
• The Praxis Medical Insights guideline cautions against combining multiple nephrotoxic medications 1, 4